Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Sunifiram and Unifiram — mechanism, side effects, legal status, and pricing.
Sunifiram (DM-235) is a synthetic non-peptide piperazine derivative marketed online as an 'ampakine-like' cognitive enhancer. Despite common branding, primary research shows it acts indirectly via the glycine-binding site of the NMDA receptor to potentiate AMPA-receptor-mediated transmission, not as a direct AMPA agonist. No human clinical trials or toxicology studies have been conducted, and sunifiram is not approved for any human or veterinary use worldwide. It is sold on the gray market without regulatory vetting.
Unifiram (DM-232) is a synthetic non-peptide small-molecule nootropic structurally related to sunifiram, though not a racetam itself. It originated from Italian academic research (University of Florence) in the early 2000s and has never progressed beyond preclinical animal studies; it is not an approved or investigational drug in any regulatory database. Unifiram is sold openly by research-chemical vendors as an unregulated laboratory reagent. No human data of any kind exist.
Sunifiram
Unifiram
Category
Legal Status
Mechanism
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
Sunifiram
Unifiram
COA corpus from Disclosed Labs — independently tested batches only.
Sunifiram
1
COAs
99.5%
Avg purity
1
Labs
Unifiram
1
COAs
99.4%
Avg purity
1
Labs
No human data exist. In olfactory-bulbectomized mice given oral sunifiram 0.01–1.0 mg/kg daily for 7–12 days, spatial reference memory (Y-maze) and short-term recognition memory (novel object recognition) improved, and impaired hippocampal CA1 long-term potentiation was restored via NMDAR-glycine-site-dependent CaMKII/PKC signaling (blocked by gavestinel). In mouse hippocampal slices, sunifiram (1–1000 nM, peaking at 10 nM with a bell-shaped dose-response) potentiated CA1 LTP via the glycine-site/PKCα/CaMKII pathway. In passive-avoidance models, sunifiram reversed amnesia in mice and rats at doses roughly four orders of magnitude lower than piracetam. No toxicology studies or human clinical trials have been conducted as of 2016.
Key references
No human data of any kind exist for unifiram; no registered clinical trials or published human studies were found. All available evidence is from rodent behavioral and in-vitro electrophysiology studies. In mice and rats, unifiram (0.001–1 mg/kg i.p. or 0.01–0.1 mg/kg oral) reversed amnesia induced by scopolamine, mecamylamine, baclofen, clonidine, and NBQX in passive-avoidance and Morris water-maze tests, at doses roughly 1,000-fold lower than piracetam, without impairing motor coordination or altering spontaneous locomotor activity. No systematic toxicology (repeat-dose, genotoxicity, carcinogenicity) studies have been published.
Sunifiram and Unifiram are both in the Cognitive category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing
Disclosed Labs